CJIP 10 - CJC-1295 no DAC and Ipamorelin
Combined Blend – CJC-1295 No DAC & Ipamorelin: Synergistic Effect: By combining CJC-1295 without DAC and Ipamorelin, the blend offers a dual approach to growth hormone secretion. CJC-1295 targets the release via the GHRH pathway, while Ipamorelin mimics the hunger hormone, giving a more complete stimulation profile. Benefits: Rapid GH Release: The no-DAC formulation of CJC-1295 provides immediate growth hormone release, while Ipamorelin further supports this release with a different mechanism of action, often leading to more substantial GH pulses. Lower Side Effects: This blend minimizes the cortisol, prolactin, and insulin secretion often seen with other GHRPs, reducing the metabolic side effects associated with long-term hGH treatments. Convenience: For research or potential therapeutic applications, this blend reduces the need for multiple injections, providing a balanced increase in GH without the prolonged action or excessive pulses that could be less optimal for certain uses. CJC-1295 without DAC (Deaconidase): Composition: This is a synthetic analogue of growth hormone-releasing hormone (GHRH) with the key modification being the exclusion of Drug Affinity Complex (DAC). This alteration allows for a shorter half-life, typically around 1-3 hours after subcutaneous administration, compared to versions with DAC which can last much longer. Function: CJC-1295 without DAC works by mimicking natural GHRH to increase the release of growth hormone from the pituitary gland. It does not have the prolonged action associated with DAC versions but can lead to a more immediate peak in GH levels post-injection. Applications: Often used in research for potential anti-aging effects, muscle growth, and fat loss. The lack of DAC reduces the duration of action but also reduces the cumulative effect, potentially lowering but not eliminating the risk of tachyphylaxis (rapid decrease in the response to a drug after repeated administration). Ipamorelin: Composition: A pentapeptide classified as a growth hormone secretagogue (GHS), similar to Ghrelin, the hunger hormone. Unlike GHRH analogues, Ipamorelin belongs to the ghrelin mimetic class. Function: It stimulates the pituitary gland to release growth hormone in a more direct fashion without significantly affecting other hormones like cortisol or prolactin, which is beneficial for minimizing side effects on the metabolism of other substances. Applications: Ipamorelin is researched for its potential in promoting lean body mass, reducing body fat, boosting skin elasticity, and aiding in bone density. Its specificity in action also makes it a desirable option for research into specific aspects of growth hormone therapy without broad hormonal disruptions. Usage Considerations: Ideal for research and clinical settings where a balance between GH stimulation and minimal side effects is sought. Not suitable for long-term/harsh cycle due to the lack of prolonged GH effect. Researchers should consider the regimen’s length and patient/subject monitoring for any adverse effects. This peptide blend represents a thoughtful combination for researchers looking into growth hormone therapy, muscle growth, and fat reduction strategies, offering a nuanced approach to stimulating growth hormone with potentially reduced metabolic impacts. Care information Store in a cool, dry place away from light. If Constituted, Please Refrigerate For long-term storage, freezing at -20°C is recommended to maintain integrity. WARNING : This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic Related products
